Who
Novo Holdings A/S
10% owner
Company insider
Files Form 4 as: 10% owner, Hemab Therapeutics Holdings; 10% owner, Avalyn Pharma; 10% owner, MapLight Therapeutics; 10% owner, IO Biotech; 10% owner, Spruce Biosciences; 10% owner, Metagenomi Therapeutics; 10% owner, Cyteir Therapeutics; 10% owner, Disc Medicine.
In numbers
- Trades disclosed
- 915
- Buys
- 88
- Sells
- 106
- Bought
- $354.8M
- Sold
- $491.3M
- Companies
- 46
- Companies where not an officer
- 46
- First trade
- 11 May 2006
- Last trade
- 4 May 2026
- Last filed
- 6 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics HoldingsBiotechnology | SEC FORM 4 Code C | —4,180,550 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —23,343 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —71,866 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —23,343 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —71,866 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —62,121 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —32,695 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —62,121 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —32,695 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | COAG Hemab Therapeutics HoldingsBiotechnology | SEC FORM 4 Code C | —4,180,550 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Code C | —3,327,734 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn PharmaBiotechnology | SEC FORM 4 Bought | $10.0M555,555 at $18.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,000,000 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —18,000,000 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,986,369 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —25,899,284 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,587,603 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —12,558,081 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,986,369 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code C | —25,899,284 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.